We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 5 minutes

Scientists have used artificial intelligence-enhanced tools to successfully propose a new combination of drugs for use against an incurable childhood brain cancer.

The approach, which is designed to expand researchers’ capabilities using AI, allowed the scientists to explore ideas on how to target children with diffuse intrinsic pontine glioma (DIPG) who have mutations in a gene called ACVR1.

The scientists found that using a drug called everolimus alongside a drug called vandetanib could enhance vandetanib's capacity to pass through the blood-brain barrier in order to treat the cancer. The proposed combination has proved effective when tested in mice and has already been tested in a small cohort of children.

Opening up new doors for cancer treatment

The study, led by scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, is an example of how use of an AI-augmented approach can open up new doors for cancer treatment by spotting new ways of combining existing medicines.

The research is published in the journal Cancer Discovery, and was funded by Brain Research UK, the DIPG Collaborative, Children with Cancer UK, Abbie’s Army, Lucas’ Legacy, The Lyla Nsouli Foundation, Cancer Research UK, and a George and the Giant Pledge donation to The Royal Marsden Cancer Charity. 

The initial hypothesis for the study came from BenevolentAI – a company that has built a leading artificial intelligence (AI) drug discovery platform and its own in-house pipeline of drug discovery programmes. Researchers at the ICR worked closely with experts at BenevolentAI to make use of the platform’s capabilities.

Uncovering insights using AI

A quarter of children with DIPG have a mutation in a gene known as ACVR1, but there is currently no treatment targeting this mutation approved for use in DIPG.

The targeted drug vandetanib, which is approved for treating thyroid cancer, acts against the ACVR1 gene, but has difficulty getting past the blood brain barrier. It is pushed back out of the brain, meaning it cannot build up to a high enough concentration in the brain to have a therapeutic effect. 

The researchers used BenevolentAI’s platform to identify drugs that could be used to target ACVR1 mutations in DIPG and suggested combining vandetanib with another drug, everolimus, which prevents vandetanib from being ejected from the brain.

The process involved scientific experts searching BenevolentAI’s biomedical knowledge graph using computational tools. The knowledge graph contains all publicly available biomedical data - as well as further information that BenevolentAI's machine learning system has ingested and 'read' from scientific articles.

Computational tools allowed scientists to explore the information in the graph and uncover insights they would not have been able to find using human reasoning alone.

Treatment extended survival in mice

A team led by scientists at the ICR showed that combining the two drugs increased the amount of vandetanib in the brains of mice with DIPG by 56 per cent. The researchers also found that the treatment extended survival in mice by 14 per cent compared with those receiving a control treatment.

The drugs identified in the study, vandetanib and everolimus, are already approved to treat other types of cancer by NICE, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), and could be repurposed for use in combination to treat children with DIPG and an ACVR1 mutation.

In the study, doctors also carried out initial tests of the drug combination in four DIPG patients.

The next step will be for the drug combination to enter clinical trials, which researchers hope will happen in the near future.

The value of AI

Study leader Professor Chris Jones, Professor of Paediatric Brain Tumour Biology at The Institute of Cancer Research, London, said:

“DIPG is a rare and aggressive childhood brain cancer, and survival rates have not changed over the past 50 years, so we desperately need to find new treatments for this disease.

“Our study demonstrates just how much AI can bring to drug discovery for cancers like DIPG, in proposing new treatment combinations that would not have been obvious to people.

“The AI system suggested using a combination of two existing drugs to treat some children with DIPG – one to target the ACVR1 mutation, and the other to sneak the first past the blood brain barrier. The treatment extended survival when we tested it in a mouse model, and we have already started testing it out in a small number of children.

“We still need a full-scale clinical trial to assess whether the treatment can benefit children, but we’ve moved to this stage much more quickly than would ever have been possible without the help of AI.”

'Bench-to-bedside approach'

Dr Fernando Carceller, Consultant in Paediatric and Adolescent Neuro-Oncology, Oak Drug Development Unit at The Royal Marsden NHS Foundation Trust, and Leader of the Paediatric & Adolescent Neuro-Oncology and Drug Development team at The Institute of Cancer Research, London, said:

“This encouraging research highlights the possibilities of harnessing Artificial Intelligence to find better cures for childhood cancers.

“Close collaboration between scientists at the ICR and clinicians at The Royal Marsden made possible this bench-to-bedside approach. The clinical results are too preliminary as to draw firm conclusions, but we are working to take this combination forward in a clinical trial for children with ACVR1-mutant DIPG.”

A 'transformative effect' on drug discovery

Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London, said:

“The use of AI promises to have a transformative effect on drug discovery, by identifying the most promising drug targets, understanding the structures of proteins from their amino acid sequence, or as here, proposing ways of combining existing drugs together to create powerful new combinations.

“In this study, use of AI has identified a drug combination which appears to have promise as a future treatment for some children with incurable brain cancer. It’s exciting to think that it could become one of the first examples of a treatment proposed by AI going on to benefit patients.”

'Promising early results'

Professor Peter Richardson, VP Pharmacology at BenevolentAI, said:

“We are pleased that our AI-assisted drug repurposing hypothesis for this new combination has shown promising early results. AI-enhanced approaches are already proving their value in expanding researchers’ capabilities to find innovative new treatment approaches - be it through uncovering new therapeutics or repurposing existing ones - not only in DIPG, but also other diseases in the future."

'A step in the right direction'

Dr Diana Martins Carvalho, first author of the study and a Postdoctoral Fellow at The Institute of Cancer Research, London, said:

“At the ICR, we are lucky enough to work with some amazing parent-led charities dedicated to funding research into DIPG. This important study would not have been possible without their support, and we are incredibly grateful for that.

“Though we still have a long way to go, I’m proud of the progress we are making to better understand DIPG and how to treat it. This study is a step in the right direction towards finding effective treatments, so that children with DIPG can have a better chance at life.”

'Vital to accelerate progress'

Abbie Misfud was six years old when she passed away from DIPG, five months after being diagnosed. Her parents Amanda and Ray set up the charity Abbie’s Army in her memory. Amanda Misfud said:

“Our support of Prof Chris Jones and the Jones lab at the ICR goes back a number of years now, we’re very proud to be connected to this study. Since Abbie lost her life to DIPG, and having witnessed so many other children pass away since, we are simply compelled and driven to help.

“One of our very first projects with Chris was supporting a PhD student and the pre-clinical work around the new discovery of ACVR1 , and its relevance to the subset of DIPG patients with these specific driving tumour mutations.

“Having something biologically relevant to treat this disease come forward to clinical study is absolutely central to our aims, any new development individually and specifically designed for DIPG treatment in the UK is hugely significant.

“Harnessing AI and any new technologies available to treat and improve outcomes will be vital to accelerate progress that all children with DIPG so desperately need.”

Reference: Carvalho DM, Richardson PJ, Olaciregui N, et al. Repurposing vandetanib plus everolimus for the treatment of ACVR1-mutant diffuse intrinsic pontine glioma. Cancer Discov. 2021. doi: 10.1158/2159-8290.CD-20-1201

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.